Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

of pipeline products and technologies and by identifying the companies with the most robust pipelines.- Develop business strategies by understanding the trends shaping and driving the global neuroendocrine carcinoma market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global neuroendocrine carcinoma market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What is the next big thing in the global neuroendocrine carcinoma market landscape? Identify, understand and capitalize.1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Neuroendocrine Carcinoma Therapeutics - Introduction 72.1 Disease Overview 72.2 Epidemiology 92.3 Risk Factors 102.4 Etiology 112.5 Symptoms 112.6 Diagnosis 122.7 Staging 162.8 Treatment and Management Pattern 192.8.1 Treatment Algorithm 192.8.2 Treatment for GI Carcinoid Tumors 192.8.3 Treatment for Pancreatic NETs/Islet Cell Tumor 212.9 Referral Pathway for GEP-NETs 222.10 GlobalData Pipeline Report Guidance 243 Neuroendocrine Carcinoma Therapeutics- Market Characterization 253.1 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Global 253.2 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) – Global 273.3 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – the US 293.4 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the US 303.5 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) –the UK
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 SoundConnect , an ... Office 365 end users the key to turning ... system by adding voice enablement and hybrid audio ... Online, a communication tool that includes presence, instant ... voice, O365 becomes a comprehensive unified communications solution. ...
(Date:10/30/2014)... October 30, 2014 James Sherley says he ... adult tissue stem cell technology since his days as a ... Philadelphia in the late 1990’s. Sherley founded the ASCTC ... company holds all the intellectual property developed in Sherley’s research ... the Massachusetts Institute of Technology (MIT), and more recently as ...
(Date:10/30/2014)... New York, NY (PRWEB) October 30, 2014 ... investment plan for its ICH Stability Testing and Package ... companies, this investment centers on a dramatic increase in ... larger volume of stability, storage and aging samples to ... first stage of this major capital expenditure has already ...
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories ... of the Board, to the National Stem Cell Ethics ... made by the Ministry of Health on behalf of the ... , More than a year after Bahamian Parliament passed the ... Perry Christie said the government has completed the accompanying regulations ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... amounts are in U.S. dollars, QUEBEC CITY, May ... TSX: AEZ), a global biopharmaceutical company focused on,endocrinology and ... quarter ended March 31, 2008., First Quarter ... second efficacy trial of the Phase ...
... Calif., May 6 Finesse Solutions, LLC,Santa ... control solutions for,life sciences process applications, announced ... of Software. Basil brings over 19 years ... a focus on,implementing high efficiency engineering, resource ...
... Genta,Incorporated (OTC Bulletin Board: GNTA) announced today ... Regulatory Authority (FINRA, formerly,the NASD) has cleared a ... stock on the Over-the-Counter Bulletin Board (OTCBB). As ... for the Company,s,common stock will begin on Wednesday, ...
Cached Biology Technology:AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7Basil Zimmo Joins Finesse Solutions as Vice-President of Software 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 3
(Date:10/29/2014)... a large cohort of kidney cancer patients in Europe ... -- and reveals an apparent link between exposure to ... Romania. , The research, by an international team led ... Innovation Centre in Montreal, underscores the importance of investigating ... found in plants of the Aristolochia genus, also has ...
(Date:10/28/2014)... (NIH) announced awards to expand the Office of ... for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases ... physician scientists at 22 consortia will work with ... and investigate new treatments for patients with rare ... million in fiscal 2014 funding from NIH. , ...
(Date:10/28/2014)... and juices are associated with a lower risk of ... University of East Anglia (UEA). , Research published ... and flavanones (both subclasses of dietary flavonoids) significantly decrease ... cause of cancer death among women. , The ... aged between 25 and 55 for more than three ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... WASHINGTON Synthetic biology promises to enable cheap, lifesaving ... suffer from malaria, and to create innovative biofuels that ... the science and its applications are raising questions: ... purposely changing the definition of what is life? ...
... Carolina, there are five strange looking "patches" cleared out ... circles carved by aliens. , They,re actually budding longleaf ... St. Louis and their collaborators at North Carolina State ... Washington have created these ecological patches with the help ...
... French . Plant researchers from ... announced a major breakthrough in a developmental process called ... reversal of what is called epigenetic silencing in plants. ... better understanding of gene regulation in the continuing quest ...
Cached Biology News:Synthetic biology: Is ethics a showstopper? 2Study on wildlife corridors shows how they work over time 2Study on wildlife corridors shows how they work over time 3Study on wildlife corridors shows how they work over time 4Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: